Heparanase is an endo-β-
glucuronidase that cleaves
heparan sulfate side chains from their
proteoglycans. Thereby,
heparanase liberates highly potent circulating
heparan sulfate-fragments (HS-fragments) and triggers the fatal and excessive inflammatory response in
sepsis. As a potential
anti-inflammatory agent for
sepsis therapy,
peptide 19-2.5 belongs to the class of synthetic anti-
lipopolysaccharide peptides; however, its activity is not restricted to
Gram-negative bacterial infection. We hypothesized that
peptide 19-2.5 interacts with
heparanase and/or HS, thereby reducing the levels of circulating HS-fragments in murine and human
sepsis. Our data indicate that the treatment of septic mice with
peptide 19-2.5 compared to untreated control animals lowers levels of plasma
heparanase and circulating HS-fragments and reduces
heparanase activity. Additionally,
mRNA levels of
heparanase in heart, liver, lung, kidney and spleen are downregulated in septic mice treated with
peptide 19-2.5 compared to untreated control animals. In humans, plasma
heparanase level and activity are elevated in
septic shock. The ex vivo addition of
peptide 19-2.5 to plasma of
septic shock patients decreases
heparanase activity but not
heparanase level. Isothermal titration calorimetry revealed a strong exothermic reaction between
peptide 19-2.5 and
heparanase and HS-fragments. However, a saturation character has been identified only in the
peptide 19-2.5 and HS interaction. In conclusion, the findings of our current study indicate that
peptide 19-2.5 interacts with
heparanase, which is elevated in murine and human
sepsis and consecutively attenuates the generation of circulating HS-fragments in systemic
inflammation. Thus,
peptide 19-2.5 seems to be a potential
anti-inflammatory agent in
sepsis.